approval
saveSKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
community read0 votes
Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 201d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 201d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 213d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 213d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 397d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 397d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 516d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalJun 18, 2024 · 839d ago
same company · ±60 days · 6
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
- approvaldivalproex sodium DR: DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvalMay 1, 2025
- approvalupadacitinib tartrate ER: RINVOQ (UPADACITINIB) — FDA approvalApr 28, 2025
- approvalatogepant: QULIPTA (ATOGEPANT) — FDA approvalJun 10, 2025
comments(0)
5-min edit window · permanent after that